Array BioPharma Inc. (NASDAQ:ARRY) Files An 8-K Results of Operations and Financial ConditionItem 2.02
On February 6, 2018, Array BioPharma Inc. issued a press release reporting results for the second quarter of fiscal year ending June 30, 2018, the full text of which is attached hereto as Exhibit 99.1. The information in Item 2.02 of this Form 8-K and the exhibit attached hereto shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
On February 6, 2018, Array issued a press release announcing overall survival data from the Phase 3 COLUMBUS trial in BRAF-Mutant Melanoma.
A copy of the press release is attached to this Form 8-K as Exhibit 99.1 and incorporated herein by reference.
| Item 2.02 | Financial Statements and Exhibits. |
(d)Exhibits
See the Exhibit Index which is hereby incorporated by reference.
EXHIBIT INDEX
ARRAY BIOPHARMA INC ExhibitEX-99.1 2 tv484978_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Array BioPharma Reports Financial Results For The Second Quarter of Fiscal 2018 - Encorafenib and binimetinib combination achieved a median overall survival (mOS) of 33.6 months in patients with BRAF-mutant melanoma in Phase 3 COLUMBUS trial – - FDA target action date under PDUFA is June 30,…To view the full exhibit click here
About Array BioPharma Inc. (NASDAQ:ARRY)
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The Company’s programs include approximately three cancer drugs, binimetinib, encorafenib and selumetinib (partnered with AstraZeneca, PLC). Its binimetinib and encorafenib are in Phase III trials in advanced cancer patients, including the COLUMBUS trial studying encorafenib in combination with binimetinib in patients with BRAF-mutant melanoma and has initiated BEACON CRC trial to study encorafenib in combination with binimetinib and cetuximab in patients with BRAF V600E-mutant colorectal cancer (BRAFm CRC). Its selumetinib is a mitogen-activated protein kinase (MEK) inhibitor for cancer, which is in Phase III trial. Its advanced clinical-stage drugs include Filanesib, ARRY-797, ASC08/Danoprevir, Ipatasertib/GDC-0068, Motolimod/VTX-2337, LOXO-101, ONT-380/ARRY-380, GDC-0575, GDC-0994 and ARRY-382.
